FindTrial
Sign In

Study on the Role and Mechanism of Indirubin Nanoparticles in Inflammatory Bowel Disease

Study on the Role and Mechanism of Indirubin Nanoparticles in Inflammatory Bowel Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115381
Enrollment
Unknown
Registered
2025-12-25
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease (ulcerative colitis and Crohn's disease

Interventions

Inflammatory Bowel disease Observation Group:None

Sponsors

Taizhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with a clear diagnosis of IBD

Exclusion criteria

Exclusion criteria: Exclude patients with intestinal infectious diseases and tumors caused by other reasons

Design outcomes

Primary

MeasureTime frame
Biology functions of neutrophils;—

Countries

China

Contacts

Public ContactChen Wenxiao

Taizhou First People's Hospital

iamathena@163.com+86 576 8401 6898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026